Skip to main content

CJC-1295 vs Retatrutide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Retatrutide

Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.

Full details →

Side-by-Side Comparison

AspectCJC-1295Retatrutide
MechanismCJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation.
Typical DosageCJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials.
AdministrationSubcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved.
Side EffectsWater retention, tingling in extremities, potential increase in cortisol and prolactin levels.Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity.
Best For

What They Have in Common

CJC-1295, Retatrutide are both commonly used for:

Key Differences

Unique to CJC-1295:

Detailed Analysis

Commonalities

Both CJC-1295 and Retatrutide are commonly used for Fat Loss.

Which Should You Choose?

Both peptides have similar evidence levels for their shared goals. Your choice may depend on specific use case, availability, or personal response.

Ready to Learn More?